CMND — Clearmind Medicine Cashflow Statement
0.000.00%
- CA$5.96m
- -CA$1.47m
Annual cashflow statement for Clearmind Medicine, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2019 October 31st | 2020 October 31st | R2021 October 31st | R2022 October 31st | 2023 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Net Income/Starting Line | -0.079 | -0.173 | -2.96 | -6.89 | -8.62 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0 | — | 0.681 | 1.85 | 3.23 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.032 | -0.023 | 0.021 | 1.24 | -0.969 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -0.047 | -0.197 | -2.25 | -3.72 | -6.3 |
Capital Expenditures | -0.008 | -0.007 | -0.026 | -0.006 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | 0.004 | -0.173 | 0 | -0.026 |
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.008 | -0.004 | -0.2 | -0.006 | -0.026 |
Financing Cash Flow Items | 0 | -0.038 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0 | 0.445 | 5.85 | 0.512 | 11.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.055 | 0.245 | 3.39 | -3.24 | 5.3 |